{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:42:51Z","timestamp":1788903771600,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cannabidiol (CBD) is the main pharmacologically active phytocannabinoid. CBD exerts an analgesic effect in several pain models, does not have side effects and has low toxicity. The data about CBD mechanisms of action in pain and its therapeutic potential in this area are limited. Here, we tested CBD effects in animal models specific for migraine. We assayed CBD distribution in plasma and in cranial areas related to migraine pain in male Sprague Dawley rats treated chronically (5\u00a0days). Successively, we tested CBD activity on the behavioral and biochemical effects induced in the acute and the chronic migraine animal models by nitroglycerin (NTG) administration. In the acute migraine model, rats received CBD (15\u00a0mg or 30\u00a0mg\/kg, i.p) 3\u00a0h after NTG (10\u00a0mg\/kg i.p.) or vehicle injection. In the chronic migraine model, rats were treated with CBD and NTG every other day over nine days with the following doses: CBD 30\u00a0mg\/kg i.p., NTG 10\u00a0mg\/kg i.p. We evaluated behavioral parameters with the open field and the orofacial formalin tests. We explored the fatty acid amide hydrolase gene expression, cytokines mRNA and protein levels in selected brain areas and CGRP serum level. CBD levels in the meninges, trigeminal ganglia, cervical spinal cord, medulla pons, and plasma were higher 1\u00a0h after the last treatment than after 24\u00a0h, suggesting that CBD penetrates but does not accumulate in these tissues. In the acute model, CBD significantly reduced NTG-induced trigeminal hyperalgesia and CGRP and cytokine mRNA levels in peripheral and central sites. In the chronic model, CBD caused a significant decrease in NTG-induced IL-6 protein levels in the medulla\u2013pons, and trigeminal ganglion. It also reduced CGRP serum levels. By contrast, CBD did not modulate TNF-alpha protein levels and fatty acid amide hydrolase (FAAH) gene expression in any of investigated areas. In both experimental conditions, there was no modulation of anxiety, motor\/exploratory behavior, or grooming. These findings show that CBD reaches brain areas involved in migraine pain after systemic administration. They also show for the first time that CBD modulates migraine-related nociceptive transmission, likely via a complex signaling mechanism involving different pathways.\n<\/jats:p>","DOI":"10.1186\/s10194-023-01589-y","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T07:02:54Z","timestamp":1683097374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine"],"prefix":"10.1186","volume":"24","author":[{"given":"Rosaria","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Francavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Demartini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Zanaboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Facchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Palmisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"1589_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"T Vos","year":"2016","unstructured":"Vos T, Allen C, Arora M et al (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet 388:1545\u20131602. https:\/\/doi.org\/10.1016\/S0140-6736(16)31678-6","journal-title":"Lancet"},{"key":"1589_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP et al (2019) Migraine and the trigeminovascular system\u201440 years and counting. Lancet Neurol 18:795\u2013804. https:\/\/doi.org\/10.1016\/S1474-4422(19)30185-1","journal-title":"Lancet Neurol"},{"key":"1589_CR3","doi-asserted-by":"publisher","first-page":"174480691876769","DOI":"10.1177\/1744806918767697","volume":"14","author":"M Su","year":"2018","unstructured":"Su M, Yu S (2018) Chronic migraine: a process of dysmodulation and sensitization. Mol Pain 14:1744806918767697. https:\/\/doi.org\/10.1177\/1744806918767697","journal-title":"Mol Pain"},{"key":"1589_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/head.12999","volume":"57","author":"SK Aurora","year":"2017","unstructured":"Aurora SK, Brin MF (2017) Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache 57:109\u2013125. https:\/\/doi.org\/10.1111\/head.12999","journal-title":"Headache"},{"key":"1589_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M et al (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97:553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015","journal-title":"Physiol Rev"},{"key":"1589_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. Cephalalgia 37:470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia"},{"key":"1589_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.phrs.2017.02.019","volume":"119","author":"L Luongo","year":"2017","unstructured":"Luongo L, Starowicz K, Maione S, Di Marzo V (2017) Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE). Pharmacol Res 119:272\u2013277. https:\/\/doi.org\/10.1016\/j.phrs.2017.02.019","journal-title":"Pharmacol Res"},{"key":"1589_CR8","doi-asserted-by":"publisher","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","volume":"27","author":"FR Bambico","year":"2007","unstructured":"Bambico FR, Katz N, Debonnel G, Gobbi G (2007) Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci 27:11700\u201311711. https:\/\/doi.org\/10.1523\/JNEUROSCI.1636-07.2007","journal-title":"J Neurosci"},{"key":"1589_CR9","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3390\/ph3082661","volume":"3","author":"E Palazzo","year":"2010","unstructured":"Palazzo E, Luongo L, de Novellis V et al (2010) The role of cannabinoid receptors in the descending modulation of pain. Pharmaceuticals 3:2661\u20132673. https:\/\/doi.org\/10.3390\/ph3082661","journal-title":"Pharmaceuticals"},{"key":"1589_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/can.2016.0009","volume":"1","author":"EB Russo","year":"2016","unstructured":"Russo EB (2016) Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res 1:154\u2013165. https:\/\/doi.org\/10.1089\/can.2016.0009","journal-title":"Cannabis Cannabinoid Res"},{"key":"1589_CR11","doi-asserted-by":"publisher","unstructured":"Greco R, Demartini C, Zanaboni AM, et al (2020) FAAH inhibition as a preventive treatment for migraine: a pre-clinical study. Neurobiol Dis 134:104624. https:\/\/doi.org\/10.1016\/j.nbd.2019.104624","DOI":"10.1016\/j.nbd.2019.104624"},{"key":"1589_CR12","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.euroneuro.2015.04.001","volume":"25","author":"C Nozaki","year":"2015","unstructured":"Nozaki C, Markert A, Zimmer A (2015) Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice. Eur Neuropsychopharmacol 25:1388\u20131396. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.04.001","journal-title":"Eur Neuropsychopharmacol"},{"key":"1589_CR13","doi-asserted-by":"publisher","unstructured":"Greco R, Demartini C, Zanaboni A, et al (2021) Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. Neurobiol Dis 147:105157. https:\/\/doi.org\/10.1016\/j.nbd.2020.105157","DOI":"10.1016\/j.nbd.2020.105157"},{"key":"1589_CR14","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1111\/bph.15208","volume":"177","author":"M McKenna","year":"2020","unstructured":"McKenna M, McDougall JJ (2020) Cannabinoid control of neurogenic inflammation. Br J Pharmacol 177:4386\u20134399. https:\/\/doi.org\/10.1111\/bph.15208","journal-title":"Br J Pharmacol"},{"key":"1589_CR15","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3390\/cells10102543","volume":"10","author":"R Greco","year":"2021","unstructured":"Greco R, Demartini C, Francavilla M et al (2021) Dual inhibition of faah and magl counteracts migraine-like pain and behavior in an animal model of migraine. Cells 10:2543. https:\/\/doi.org\/10.3390\/cells10102543","journal-title":"Cells"},{"key":"1589_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000521683","volume":"107","author":"CA Legare","year":"2022","unstructured":"Legare CA, Raup-Konsavage WM, Vrana KE (2022) Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals. Pharmacology 107:131\u2013149. https:\/\/doi.org\/10.1159\/000521683","journal-title":"Pharmacology"},{"key":"1589_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.01259","volume":"9","author":"S Vu\u010dkovic","year":"2018","unstructured":"Vu\u010dkovic S, Srebro D, Vujovic KS et al (2018) Cannabinoids and pain: new insights from old molecules. Front Pharmacol 9:1\u201319. https:\/\/doi.org\/10.3389\/fphar.2018.01259","journal-title":"Front Pharmacol"},{"key":"1589_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/WCO.0000000000000688","volume":"32","author":"C Tassorelli","year":"2019","unstructured":"Tassorelli C, Greco R, Silberstein SD (2019) The endocannabinoid system in migraine: from bench to pharmacy and back. Curr Opin Neurol 32:405\u2013412. https:\/\/doi.org\/10.1097\/WCO.0000000000000688","journal-title":"Curr Opin Neurol"},{"key":"1589_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7759\/cureus.32622","volume":"14","author":"ML Sherpa","year":"2022","unstructured":"Sherpa ML, Shrestha N, Ojinna BT et al (2022) Efficacy and safety of medical marijuana in migraine headache: a systematic review. Cureus 14:1\u20138. https:\/\/doi.org\/10.7759\/cureus.32622","journal-title":"Cureus"},{"key":"1589_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2:139\u2013154. https:\/\/doi.org\/10.1089\/can.2016.0034","journal-title":"Cannabis Cannabinoid Res"},{"key":"1589_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.9740\/mhc.2016.11.277","volume":"6","author":"DL Boggs","year":"2016","unstructured":"Boggs DL, Peckham A, Boggs AA, Ranganathan M (2016) Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the \u201c\u2018weed\u2019\u201d, a pharmacodynamic discussion. Mental Health Clinician 6:277\u2013284. https:\/\/doi.org\/10.9740\/mhc.2016.11.277","journal-title":"Mental Health Clinician"},{"key":"1589_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/bph.14440","volume":"176","author":"M Tham","year":"2019","unstructured":"Tham M, Yilmaz O, Alaverdashvili M et al (2019) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 176:1455\u20131469. https:\/\/doi.org\/10.1111\/bph.14440","journal-title":"Br J Pharmacol"},{"key":"1589_CR23","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805. https:\/\/doi.org\/10.1111\/bph.13250","journal-title":"Br J Pharmacol"},{"key":"1589_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejphar.2006.11.006","volume":"556","author":"B Costa","year":"2007","unstructured":"Costa B, Trovato AE, Comelli F et al (2007) The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556:75\u201383. https:\/\/doi.org\/10.1016\/j.ejphar.2006.11.006","journal-title":"Eur J Pharmacol"},{"key":"1589_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21228870","volume":"21","author":"J Mlost","year":"2020","unstructured":"Mlost J, Bryk M, Starowicz K (2020) Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci 21:1\u201322. https:\/\/doi.org\/10.3390\/ijms21228870","journal-title":"Int J Mol Sci"},{"key":"1589_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","volume":"134","author":"T Bisogno","year":"2001","unstructured":"Bisogno T, Hanu\u0161 L, De Petrocellis L et al (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134:845\u2013852. https:\/\/doi.org\/10.1038\/sj.bjp.0704327","journal-title":"Br J Pharmacol"},{"key":"1589_CR27","doi-asserted-by":"publisher","unstructured":"Leweke FM, Piomelli D, Pahlisch F, et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94. https:\/\/doi.org\/10.1038\/tp.2012.15","DOI":"10.1038\/tp.2012.15"},{"key":"1589_CR28","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.freeradbiomed.2011.01.007","volume":"51","author":"GW Booz","year":"2011","unstructured":"Booz GW (2011) Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 51:1054\u20131061. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2011.01.007","journal-title":"Free Radic Biol Med"},{"key":"1589_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","volume":"16","author":"M Zimmermann","year":"1983","unstructured":"Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109\u2013110. https:\/\/doi.org\/10.1016\/0304-3959(83)90201-4","journal-title":"Pain"},{"key":"1589_CR30","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/biomedicines10081853","volume":"10","author":"F Mottarlini","year":"2022","unstructured":"Mottarlini F, Fumagalli M, Castillo-D\u00edaz F et al (2022) Single and repeated exposure to cannabidiol differently modulate BDNF expression and signaling in the Cortico-Striatal Brain Network. Biomedicines 10:1853. https:\/\/doi.org\/10.3390\/biomedicines10081853","journal-title":"Biomedicines"},{"key":"1589_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.915004","volume":"13","author":"V Franco","year":"2022","unstructured":"Franco V, Palmisani M, Marchiselli R et al (2022) On-line solid phase extraction high performance liquid chromatography method coupled with tandem mass spectrometry for the therapeutic monitoring of cannabidiol and 7-Hydroxy-cannabidiol in human serum and saliva. Front Pharmacol 13:1\u201311. https:\/\/doi.org\/10.3389\/fphar.2022.915004","journal-title":"Front Pharmacol"},{"key":"1589_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01374-9","volume":"23","author":"H Chen","year":"2022","unstructured":"Chen H, Tang X, Li J et al (2022) IL-17 crosses the blood\u2013brain barrier to trigger neuroinflammation: a novel mechanism in nitroglycerin-induced chronic migraine. Journal of Headache and Pain 23:1\u201318. https:\/\/doi.org\/10.1186\/s10194-021-01374-9","journal-title":"Journal of Headache and Pain"},{"key":"1589_CR33","doi-asserted-by":"publisher","unstructured":"Demartini C, Greco R, Francavilla M, et al (2022) Modelling migraine-related features in the nitroglycerin animal model: Trigeminal hyperalgesia is associated with affective status and motor behavior. Physiol Behav 256:113956. https:\/\/doi.org\/10.1016\/j.physbeh.2022.113956","DOI":"10.1016\/j.physbeh.2022.113956"},{"key":"1589_CR34","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.3390\/cells11193092","volume":"11","author":"R Greco","year":"2022","unstructured":"Greco R, Demartini C, Francavilla M et al (2022) Antagonism of CGRP receptor: central and peripheral mechanisms and mediators in an animal model of chronic migraine. Cells 11:3092. https:\/\/doi.org\/10.3390\/cells11193092","journal-title":"Cells"},{"key":"1589_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/head.14267","volume":"62","author":"R Greco","year":"2022","unstructured":"Greco R, Demartini C, Zanaboni AM et al (2022) The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache 62:227\u2013240. https:\/\/doi.org\/10.1111\/head.14267","journal-title":"Headache"},{"key":"1589_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.phrs.2017.05.005","volume":"121","author":"C Rong","year":"2017","unstructured":"Rong C, Lee Y, Carmona NE et al (2017) Cannabidiol in medical marijuana: research vistas and potential opportunities. Pharmacol Res 121:213\u2013218. https:\/\/doi.org\/10.1016\/j.phrs.2017.05.005","journal-title":"Pharmacol Res"},{"key":"1589_CR37","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1073\/pnas.0511232103","volume":"103","author":"EJ Carrier","year":"2006","unstructured":"Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 103:7895\u20137900. https:\/\/doi.org\/10.1073\/pnas.0511232103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1589_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2018.00487","volume":"11","author":"C Muller","year":"2019","unstructured":"Muller C, Morales P, Reggio PH (2019) Cannabinoid ligands targeting TRP channels. Front Mol Neurosci 11:1\u201315. https:\/\/doi.org\/10.3389\/fnmol.2018.00487","journal-title":"Front Mol Neurosci"},{"key":"1589_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/ene.13367","volume":"24","author":"M Nicolodi","year":"2017","unstructured":"Nicolodi M, Sandoval V, Torrini A (2017) Therapeutic use of cannabinoids-dose finding, effects and pilot data of effects in chronic migraine and cluster headache. Eur J Neurol 24:287. https:\/\/doi.org\/10.1111\/ene.13367","journal-title":"Eur J Neurol"},{"key":"1589_CR40","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/jcm11061479","volume":"11","author":"F Lo Castro","year":"2022","unstructured":"Lo Castro F, Baraldi C, Pellesi L, Guerzoni S (2022) Clinical evidence of cannabinoids in migraine: a narrative review. J Clin Med 11:1479. https:\/\/doi.org\/10.3390\/jcm11061479","journal-title":"J Clin Med"},{"key":"1589_CR41","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"S Deiana","year":"2012","unstructured":"Deiana S, Watanabe A, Yamasaki Y et al (2012) Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u0394 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behav. Psychopharmacology 219:859\u2013873. https:\/\/doi.org\/10.1007\/s00213-011-2415-0","journal-title":"Psychopharmacology"},{"key":"1589_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2011.12.043","volume":"678","author":"A Ribeiro","year":"2012","unstructured":"Ribeiro A, Ferraz-De-Paula V, Pinheiro ML et al (2012) Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A 2A receptor. Eur J Pharmacol 678:78\u201385. https:\/\/doi.org\/10.1016\/j.ejphar.2011.12.043","journal-title":"Eur J Pharmacol"},{"key":"1589_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00210-004-0871-3","volume":"369","author":"B Costa","year":"2004","unstructured":"Costa B, Colleoni M, Conti S et al (2004) Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369:294\u2013299. https:\/\/doi.org\/10.1007\/s00210-004-0871-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1589_CR44","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1089\/can.2021.0108","volume":"7","author":"DE Sepulveda","year":"2022","unstructured":"Sepulveda DE, Morris DP, Raup-Konsavage WM et al (2022) Evaluating the antinociceptive efficacy of cannabidiol alone or in combination with morphine using the formalin test in male and female mice. Cannabis Cannabinoid Res 7:648\u2013657. https:\/\/doi.org\/10.1089\/can.2021.0108","journal-title":"Cannabis Cannabinoid Res"},{"key":"1589_CR45","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1177\/0269881118805495","volume":"32","author":"A Viudez-Mart\u00ednez","year":"2018","unstructured":"Viudez-Mart\u00ednez A, Garc\u00eda-Guti\u00e9rrez MS, Manzanares J (2018) Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress. J Psychopharmacol 32:1379\u20131384. https:\/\/doi.org\/10.1177\/0269881118805495","journal-title":"J Psychopharmacol"},{"key":"1589_CR46","doi-asserted-by":"publisher","unstructured":"Vuolo F, Petronilho F, Sonai B, et al (2015) Evaluation of serum cytokines levels and the role of cannabidiol treatment in animal model of asthma. Mediators Inflamm 2015:538670. https:\/\/doi.org\/10.1155\/2015\/538670","DOI":"10.1155\/2015\/538670"},{"key":"1589_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/08923973.2014.976794","volume":"37","author":"A Ribeiro","year":"2015","unstructured":"Ribeiro A, Almeida VI, Costola-De-Souza C et al (2015) Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacol Immunotoxicol 37:35\u201341. https:\/\/doi.org\/10.3109\/08923973.2014.976794","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"1589_CR48","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejphar.2012.09.053","volume":"697","author":"T Barichello","year":"2012","unstructured":"Barichello T, Ceretta RA, Generoso JS et al (2012) Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur J Pharmacol 697:158\u2013164. https:\/\/doi.org\/10.1016\/j.ejphar.2012.09.053","journal-title":"Eur J Pharmacol"},{"key":"1589_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2013.00158","volume":"7","author":"CE Onore","year":"2013","unstructured":"Onore CE, Careaga M, Babineau BA et al (2013) Inflammatory macrophage phenotype in BTBR T+tf\/J mice. Front Neurosci 7:1\u20139. https:\/\/doi.org\/10.3389\/fnins.2013.00158","journal-title":"Front Neurosci"},{"key":"1589_CR50","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1124\/jpet.119.263319","volume":"373","author":"SC Britch","year":"2020","unstructured":"Britch SC, Goodman AG, Wiley JL et al (2020) Antinociceptive and immune effects of Delta-9-tetrahydrocannabinol or cannabidiol in male versus female rats with persistent inflammatory pain. J Pharmacol Exp Ther 373:416\u2013428. https:\/\/doi.org\/10.1124\/jpet.119.263319","journal-title":"J Pharmacol Exp Ther"},{"key":"1589_CR51","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.2147\/JPR.S258433","volume":"13","author":"U Anand","year":"2020","unstructured":"Anand U, Jones B, Korchev Y et al (2020) CBD effects on TRPV1 signaling pathways in cultured drg neurons. J Pain Res 13:2269\u20132278. https:\/\/doi.org\/10.2147\/JPR.S258433","journal-title":"J Pain Res"},{"key":"1589_CR52","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.1523\/JNEUROSCI.0504-08.2008","volume":"28","author":"N Qin","year":"2008","unstructured":"Qin N, Neeper MP, Liu Y et al (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231\u20136238. https:\/\/doi.org\/10.1523\/JNEUROSCI.0504-08.2008","journal-title":"J Neurosci"},{"key":"1589_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/eos.12158","volume":"123","author":"H Qiao","year":"2015","unstructured":"Qiao H, Gao Y, Zhang C, Zhou H (2015) Increased expression of TRPV1 in the trigeminal ganglion is involved in orofacial pain during experimental tooth movement in rats. Eur J Oral Sci 123:17\u201323. https:\/\/doi.org\/10.1111\/eos.12158","journal-title":"Eur J Oral Sci"},{"key":"1589_CR54","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1017\/S1461145712001502","volume":"16","author":"AC Campos","year":"2013","unstructured":"Campos AC, Ortega Z, Palazuelos J et al (2013) The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16:1407\u20131419. https:\/\/doi.org\/10.1017\/S1461145712001502","journal-title":"Int J Neuropsychopharmacol"},{"key":"1589_CR55","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1017\/S1461145709990605","volume":"13","author":"LE Long","year":"2010","unstructured":"Long LE, Chesworth R, Huang XF et al (2010) A behavioural comparison of acute and chronic 9- tetrahydrocannabinol and cannabidiol in C57BL\/6JArc mice. Int J Neuropsychopharmacol 13:861\u2013876. https:\/\/doi.org\/10.1017\/S1461145709990605","journal-title":"Int J Neuropsychopharmacol"},{"key":"1589_CR56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s00213-006-0356-9","volume":"186","author":"SA Varvel","year":"2006","unstructured":"Varvel SA, Wiley JL, Yang R et al (2006) Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 186:226\u2013234. https:\/\/doi.org\/10.1007\/s00213-006-0356-9","journal-title":"Psychopharmacology"},{"key":"1589_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life12050652","volume":"12","author":"F Calapai","year":"2022","unstructured":"Calapai F, Cardia L, Calapai G et al (2022) Effects of cannabidiol on locomotor activity. Life 12:1\u201317. https:\/\/doi.org\/10.3390\/life12050652","journal-title":"Life"},{"key":"1589_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nmo.13756","volume":"32","author":"DD Wei","year":"2020","unstructured":"Wei DD, Wang HC, Yang JN et al (2020) Effects of O-1602 and CBD on TNBS-induced colonic disturbances. Neurogastroenterol Motil 32:1\u201311. https:\/\/doi.org\/10.1111\/nmo.13756","journal-title":"Neurogastroenterol Motil"},{"key":"1589_CR59","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3233\/JAD-191242","volume":"74","author":"G Watt","year":"2020","unstructured":"Watt G, Shang K, Zieba J et al (2020) Chronic treatment with 50 mg\/kg cannabidiol improves cognition and moderately reduces A\u03b240 Levels in 12-month-old male A\u03b2PPswe\/PS1\u0394E9 transgenic mice. J Alzheimers Dis 74:937\u2013950. https:\/\/doi.org\/10.3233\/JAD-191242","journal-title":"J Alzheimers Dis"},{"key":"1589_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/can.2020.0105","volume":"6","author":"FR Henshaw","year":"2021","unstructured":"Henshaw FR, Dewsbury LS, Lim CK, Steiner GZ (2021) The effects of cannabinoids on pro-and anti-inflammatory cytokines: a systematic review of in vivo studies. Cannabis Cannabinoid Res 6:177\u2013195. https:\/\/doi.org\/10.1089\/can.2020.0105","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"1589_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/0333102420949201","volume":"41","author":"R Greco","year":"2021","unstructured":"Greco R, Demartini C, Zanaboni AM et al (2021) Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: a pilot study. Cephalalgia 41(2):185\u2013196. https:\/\/doi.org\/10.1177\/0333102420949201","journal-title":"Cephalalgia"},{"key":"1589_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000489141","volume":"1","author":"F Grotenhermen","year":"2018","unstructured":"Grotenhermen F (2018) Franjo Grotenhermen Med Cannabis Cannabinoids 1:5. https:\/\/doi.org\/10.1159\/000489141","journal-title":"Franjo Grotenhermen Med Cannabis Cannabinoids"},{"key":"1589_CR63","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/mol.110.068940","volume":"80","author":"NB Ruparel","year":"2011","unstructured":"Ruparel NB, Patwardhan AM, Akopian AN, Hargreaves KM (2011) Desensitization of transient receptor potential ankyrin 1 (TRPA1) by the TRP vanilloid 1-selective cannabinoid arachidonoyl-2 chloroethanolamine. Mol Pharmacol 80:117\u2013123. https:\/\/doi.org\/10.1124\/mol.110.068940","journal-title":"Mol Pharmacol"},{"key":"1589_CR64","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.npep.2011.03.005","volume":"45","author":"MA Engel","year":"2011","unstructured":"Engel MA, Izydorczyk I, Mueller-Tribbensee SM et al (2011) Inhibitory CB1 and activating\/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin. Neuropeptides 45:229\u2013237. https:\/\/doi.org\/10.1016\/j.npep.2011.03.005","journal-title":"Neuropeptides"},{"key":"1589_CR65","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"S Iyengar","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59:659\u2013681. https:\/\/doi.org\/10.1111\/head.13529","journal-title":"Headache"},{"key":"1589_CR66","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1021\/cn5000524","volume":"5","author":"FA Iannotti","year":"2014","unstructured":"Iannotti FA, Hill CL, Leo A et al (2014) Nonpsychotropic plant cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), activate and desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 5:1131\u20131141. https:\/\/doi.org\/10.1021\/cn5000524","journal-title":"ACS Chem Neurosci"},{"key":"1589_CR67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbi.2018.09.014","volume":"74","author":"AB Sonego","year":"2018","unstructured":"Sonego AB, Prado DS, Vale GT et al (2018) Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPAR\u03b3 receptors. Brain Behav Immun 74:241\u2013251. https:\/\/doi.org\/10.1016\/j.bbi.2018.09.014","journal-title":"Brain Behav Immun"},{"key":"1589_CR68","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/abbs\/gmx073","volume":"49","author":"A Vall\u00e9e","year":"2017","unstructured":"Vall\u00e9e A, Lecarpentier Y, Guillevin R, Vall\u00e9e JN (2017) Effects of cannabidiol interactions with Wnt\/\u03b2-catenin pathway and PPAR\u03b3 on oxidative stress and neuroinflammation in Alzheimer\u2019s disease. Acta Biochim Biophys Sin (Shanghai) 49:853\u2013866. https:\/\/doi.org\/10.1093\/abbs\/gmx073","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"1589_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pneurobio.2019.02.002","volume":"177","author":"C Demartini","year":"2019","unstructured":"Demartini C, Greco R, Zanaboni AM et al (2019) Nitroglycerin as a comparative experimental model of migraine pain: from animal to human and back. Prog Neurobiol 177:15\u201332. https:\/\/doi.org\/10.1016\/j.pneurobio.2019.02.002","journal-title":"Prog Neurobiol"},{"issue":"6","key":"1589_CR70","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s0301-0082(98)00071-9","volume":"57","author":"C Tassorelli","year":"1999","unstructured":"Tassorelli C, Joseph SA, Buzzi MG, Nappi G (1999) The effects on the central nervous system of nitroglycerin - Putative mechanisms and mediators. Prog Neurobiol 57(6):607\u2013624. https:\/\/doi.org\/10.1016\/s0301-0082(98)00071-9","journal-title":"Prog Neurobiol"}],"updated-by":[{"DOI":"10.1186\/s10194-023-01605-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000}}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01589-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01589-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T10:02:52Z","timestamp":1685959372000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01589-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1589"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01589-y","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s10194-023-01605-1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-023-01605-1","URL":"https:\/\/doi.org\/10.1186\/s10194-023-01605-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CT has received personal fees for the participation in advisory boards and\/or scientific symposia from Abbvie, Domp\u00e9, Eli Lilly, Novartis, Lundbeck and Teva. Her institution has received payments for sponsored clinical trials or investigator-initiated trials from Abbvie, Eli Lilly, Novartis, Lundbeck and Teva. The other authors have no conflicts of interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}